(NewsDirect)
G Medical InnovationsHoldings Ltd. (NASDAQ:GMVD) (the "Company"), a telehealth,medical device, and remote patient monitoring company providingclinical-grade solutions for consumers, medical professionals, andhealthcare institutions, today announced plans to open as many as 25Covid-19 testing centers in California in Q1, 2022. Known for itsgroundbreaking technology, remote patient monitoring devices andservices utilized by hospitals and cardiologists across the country,GMedical’s innovative Prizma monitoring device will be offereddirect-to-consumer for the first time at these testing locations, aspart of an aggressive company direct-to-consumer strategy.
Prizma is auser-friendly cell phone-sized device that can help monitor user’svital signs, providing to-the-minute readings for ECG, temperature,oxygen saturation, heart rate, stress levels and blood pressure, helptrack body weight and glucose levels. Data is presented directly tothe user and the designated care provider.
G Medical’s remotepatient monitoring center can alert users to readings that may be acause for concern.
Prizma can also be prescribed by physicians to patients withcardiac or respiratory disease, diabetes and other health issues.
With theexplosive growth in demand for Covid testing across the country, GMedical expects its new California locations to boost Prizma sales.
“By offeringPrizma at our Covid19 testing sites we are empowering consumers tomeasure and monitor their vital signs post testing, in the comfort oftheir own home,” said G Medical CEO Dr. Yacov Geva. “This uniqueopportunity to introduce our Prizma device to customers face-to-faceat the point of sale is an important step forward in our company’sdirect-to-consumer initiative.”
Prominent Santa Monica physician Dr. Rand McClainagrees. “G Medical’s Prizma vital sign monitoring device canprovide ‘next level’ of care, by empowering patients to measureand record their vital signs daily .”
Telehealth services andthe use of remote patient monitoring more than doubled from 2018 to2020, and that growth continues, according to a recent report by theAmerican Medical Association (AMA). Within this industry, G MedicalInnovations is well positioned as a next-generation mobile health(mHealth) and e-health company that develops and markets its clinicaland consumer medical-grade health monitoring solutions, and offersend-to-end support for e-health projects. With extensive experience inthe field of digital health and project management, GMedicalInnovations is committed to raising the global level of healthcare byempowering caregivers and patients to better monitor, manage andimprove clinical and personal health outcomes.
About G MedicalInnovations Holdings Ltd.
G Medical Innovations Holdings Ltd. Is an earlycommercial stage healthcare company engaged in the development of nextgeneration mHealth and telemedicine solutions and monitoring serviceplatforms. The Company’s solutions and services can empowerconsumers, patients and providers to better monitor, manage andimprove clinical and personal health outcomes, especially for thosewho suffer from cardiovascular disease (or CVD), pulmonary disease anddiabetes. The Company’s current product lines consist of its Prizmamedical device (or Prizma), a clinical grade device that can transformalmost any smartphone into a medical monitoring device enabling bothhealthcare providers and individuals to monitor, manage and share awide range of vital signs and biometric indicators; its ExtendedHolter Patch System, a multi-channel patient-worn biosensor thatcaptures electrocardiography (or ECG) data continuously, including itsQT Syndrome Prolongation Detection Capabilities Patch. In addition,the Company is developing its Wireless Vital Signs Monitoring System(or VSMS), which is expected to provide full, continuous and real timemonitoring of a wide range of vital signs and biometrics. Itsmonitoring services include provision of Independent DiagnosticTesting Facility (or IDTF) monitoring services and private monitoringservices.
Forward-LookingStatements
This press release contains forward-looking statements withinthe meaning of the “safe harbor” provisions of the PrivateSecurities Litigation Reform Act of 1995 and other Federal securitieslaws. Words such as “expects,” “anticipates,” “intends,”“plans,” “believes,” “seeks,” “estimates” and similarexpressions or variations of such words are intended to identifyforward-looking statements. Because such statements deal with futureevents and are based on G Medical’s current expectations, they aresubject to various risks and uncertainties, and actual results,performance or achievements of G Medical could differ materially fromthose described in or implied by the statements in this press release.For example, G Medical is using forward-looking statements when itdiscusses plans to open as many as 25 Covid-19 testing centers inCalifornia in Q1, 2022, its direct-to-consumer strategy and thebenefits and advantages of its Prizma medical device. Theforward-looking statements contained or implied in this press releaseare subject to other risks and uncertainties, including thosediscussed under the heading “Risk Factors” in G Medical’sprospectus filed pursuant to Rule 424(b)(4), filed with the Securitiesand Exchange Commission (“SEC”) on June 28, 2021, and in anysubsequent filings with the SEC. Except as otherwise required by law,G Medical undertakes no obligation to publicly release any revisionsto these forward-looking statements to reflect events or circumstancesafter the date hereof or to reflect the occurrence of unanticipatedevents. References and links to websites have been provided as aconvenience, and the information contained on such websites is notincorporated by reference into this press release. G Medical is notresponsible for the contents of third-partywebsites.
Contact Details
G MedicalInnovations Holdings Ltd.
G Medical Service
+9728-958-4777
CompanyWebsite
Copyright (c) 2021 TheNewswire - All rights reserved.